Elevated PREOPERATIVE CARCINOEMBRYONIC ANTIGEN (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer

World Journal of Surgery

Volumn 37, Issue 1, 2013, Pages 208-213

  Peng, Yifan ^a   Wang, Lin ^a   Gu, Jin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; COLON TUMOR; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84871815222     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-012-1814-7     Document Type: Article

References (49)

1. Edge SB, Byrd DR (2010) AJCC cancer staging manual, 7th edn. Springer, New York 648
2. Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8-29
3. Sato H, Maeda K, Koide Y (2011) Prognostic factor of stage II colon cancer. Nihon Rinsho 69(Suppl 3):189-192
4. Betge J, Langner C, Rehak P (2011) Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer. Cancer 118:2184
5. Kopetz S, Freitas D, Calabrich AFC et al (2008) Adjuvant chemotherapy for stage II colon cancer. Oncology (Williston Park) 22:260-270 discussion 270, 273, 275
6. Martin RC (2006) Adjuvant treatment of stage II colon cancer: is there a true no-chemotherapy group? Ann Surg Oncol 13:766-767
7. Wille-Jorgensen P (2005) No clear evidence for adjuvant therapy in people with stage II colon cancer. Cancer Treat Rev 31:147-150
8. Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419
9. O'Connor ES, Greenblatt DY, LoConte NK et al (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29:3381-3388
10. Ochs AM, Wong L, Kakani V et al (2004) Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer 4:262-267
11. Grossman SR, Lyle S, Resnick MB et al (2007) p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. Clin Cancer Res 13:5798-5804
12. Hohenberger W, Weber K, Matzel K et al (2009) Standardized surgery for colonic cancer: complete mesocolic excision and central ligation - technical notes and outcome. Colorectal Dis 11:354-364 Discussion 364-365
13. Jakob C, Liersch T, Meyer W et al (2008) Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol 14:1060-1066
14. Figueredo A, Charette ML, Maroun J et al (2004) Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22:3395-3407
15. Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797-1806
16. Ogata Y, Murakami H, Sasatomi T et al (2009) Elevated preoperative serum carcinoembrionic antigen level may be an effective indicator for needing adjuvant chemotherapy after potentially curative resection of stage II colon cancer. J Surg Oncol 99:65-70
17. Burdy G, Panes Y, Alves A et al (2001) Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 44:1682-1688
18. Compton CC, Fielding LP, Burghart LJ et al (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979-994
19. Poincloux L, Durando X, Seitz JF et al (2009) Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surg Oncol 18:357-365
20. Schetter AJ, Leung SY, Sohn JJ et al (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425-436
21. Bates RC, Bellovin DI, Brown C et al (2005) Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 115:339-347
22. Nakamura T, Mitomi H, Kanazawa H et al (2008) Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum 51:568-572
23. Logan-Collins JM, Lowy AM, Robinson-Smith TM et al (2008) VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 15:738-744
24. AJCC Cancer Staging Handbook (2010), AJCC cancer staging handbook. 7th edn. New York, Springer
25. Burgess RE (1986) Carcinoembryonic antigen. Ann Intern Med 104:888 (letter to the editor)
26. Compton C, Fenoglio-Preiser CM, Pettigrew N et al (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88:1739-1757
27. Locker GY, Hamilton S, Harris J et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327
28. QUASAR Collaborative Group (2000) Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 355(9215):1588-1596
29. Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116
30. Van Cutsem E, Labianca R, Bodoky G et al (2009) Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117-3125
31. Park YJ, Park KJ, Park J-G et al (1999) Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg 23:721-726. doi: 10.1007/PL00012376
32. Sener SF, Imperato JP, Chmiel J et al (1989) The use of cancer registry data to study preoperative carcinoembryonic antigen level as an indicator of survival in colorectal cancer. CA Cancer J Clin 39:50-57
33. Yeh CY, Hsieh PS, Chiang JM et al (2011) Preoperative carcinoembryonic antigen elevation in colorectal cancer. Hepatogastroenterology 58:1171-1176
34. Yang XQ, Chen C, Wang F-B et al (2011) Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer. Asian Pac J Cancer Prev 12:1251-1256
35. Huh JW, Oh BR, Kim HR et al (2010) Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol 101:396-400
36. Sun LC, Chu KS, Cheng SC et al (2009) Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment. BMC Cancer 9:288
37. Takagawa R, Fujii S, Mitsuoyshi O et al (2008) Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol 15:3433-3439
38. Roselli M, Guadagni F, Martini F et al (2003) Association between serum carcinoembryonic antigen and endothelial cell adhesion molecules in colorectal cancer. Oncology 65:132-138
39. Tabuchi Y, Deguchi H, Imanishi K et al (1987) Comparison of carcinoembryonic antigen levels between portal and peripheral blood in patients with colorectal cancer. Correlation with histopathologic variables. Cancer 59:1283-1288
40. Padilla D, Cubo T, Villarejo P et al (2007) Molecular profile of node-negative colorectal cancer of poor prognosis using immunohistochemical determination of p53, Ki67, VEGF, and metalloproteinase-9. Rev Esp Enferm Dig 99:424-425
41. Allegra CJ, Palk S, Colangelo LH et al (2003) Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21:241-250
42. Ishida H, Miwa H, Tatsuta M et al (2004) Ki-67 and CEA expression as prognostic markers in Dukes' C colorectal cancer. Cancer Lett 207:109-115
43. Visco V, Belleudi F, Marchese C et al (2004) Differential response to keratinocyte growth factor receptor and epidermal growth factor receptor ligands of proliferating and differentiating intestinal epithelial cells. J Cell Physiol 200:31-44
44. Graziano F, Cascinu S (2003) Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 14:1026-1038
45. Maksimovic S (2005) Laboratory-immunology indicators according as prognostic factors of patients with colon and rectum cancer. Med Arh 59:7-10
46. Sato H, Maeda K, Sugihara K et al (2011) High-risk stage II colon cancer after curative resection. J Surg Oncol 104:45-52
47. Prandi M, Lionetto R, Bini A et al (2002) Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 235:458-463
48. Nanni O, Volpi A, Frassineti GL et al (2002) Role of biological markers in the clinical outcome of colon cancer. Br J Cancer 87:868-875
49. Caro JJ, Salas M, Ward A et al (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a system[at]ic, quantitative review. Cancer 91:2214-2221